anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Persistent knee pain in patients around the fifth decade of life is a frequent cause of attention in rehabilitation consultations. The most common cause of diagnosis is knee osteoarthritis, considering the existence of different degrees seen in simple radiographies. The advanced degrees present joint space reduction, osteophytosis and subchondral sclerosis; however, in the initial degrees, the findings are more subtle and sometimes nonexistent for conventional radiology. Clinical ultrasound has partly come to fill this «diagnostic gap», making it possible to detect meniscal extrusions and small osteophytes as signs of incipient osteoarthritis and to relate them as triggers of pain. In clinical practice we find a group of patients who, with little or no radiological alterations, present persistent and severe pain with medial predominance in most cases. These, until the appearance of the current evidence, were subsidiaries of meniscectomies. At this moment, when meniscectomies are not recommended, it is necessary to find a treatment for those cases in which conservative and non-ablative interventional treatment has failed. In this context, the possibility of using radiofrequency arises. Its use is widespread in the case of tricompartmental and advanced osteoarthritis. However, little data is available on its usefulness in cases of medial meniscal extrusion. It seems that thermal radiofrequency has greater effects than pulsed radiofrequency. We present a clinical case where thermal radiofrequency of the medial genicular nerves of the knee is proposed as a therapeutic alternative for chronic pain secondary to medial meniscal extrusion associated with incipient knee osteoarthritis, with the result of a decrease in pain (VAS 8 before treatment, VAS 1 after one year), subjective improvement of 80% and gait capacity.
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided as part of this invention that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology - such as neovascularization and vaso-obliteration - that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
This study is a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial to evaluate the efficacy, safety and immunogenicity of a single dose of Live-Attenuated influenza Vaccine(LAIV) among healthy children and adolescents aged 3-17 years old. The subjects will be randomized in a 1:1 ratio of LAIV to placebo. Each subject will be vaccinated with a single dose of LAIV or Placebo. For evaluation of efficacy, subjects meeting the protocol-defined clinical case definition the 14th day post-vaccination will have a nasal swab collected for testing by RT-PCR or virus culture for evidence of influenza virus infection. All adverse events will be collected 30 minutes, 0-30 days after vaccination and all serious adverse events during the entire trial period. Blood samples will be collected from a part of subjects before vaccination and at the 30th day after immunization. Serum samples will be centrifuged for detection of antibodies to H1N1, H3N2, and influenza B.
Liquid compositions having reduced oiliness when taken orally, comprise a glyceride ester of a fatty acid or an ethyl ester of the fatty acid fraction of an unsaturated glyceride oil, and as an emulsifying agent a fatty acid ester of sorbitan or polyethylene glycol wherein the fatty acid moiety has 10 to 22 carbon atoms, the emulsifying agent being present in an amount from 0.5 to 5.0% by weight of the glyceride ester or ethyl ester whereby the composition forms an oil-in-water emulsion when mixed with twice its volume of water.  The glyceride ester may be any animal or vegetable glyceride oil, e.g. cod liver oil and maize oil.  Other esters disclosed are the monoglyceride of maize oil fatty acids and the ethyl esters of the polyunsaturated fatty acid fraction of cod liver oil. Emulsifiers specified are sorbitan mono-oleate and polyethylene glycol mono-oleate.  A flavouring agent such as mint, caramel or saccharin may be included in the composition. Also, the composition may be admixed with milk or fruit juice.ALSO:Liquid medicinal compositions having reduced oiliness when taken orally, comprise a glyceride ester of a fatty acid or an ethyl ester of the fatty acid fraction of an unsaturated glyceride oil, and as an emulsifying agent a fatty acid ester of sorbitan or polyethylene glycol wherein the fatty acid moiety has 10 to 22 carbon atoms, the emulsifying agent being present in an amount from 0.5 to 5.0% by weight of the glyceride ester or ethyl ester whereby the composition forms an oil-in-water emulsion when mixed with twice its volume of water.  The glyceride ester may be any animal or vegetable glyceride oil, e.g. cod liver oil and maize oil.  Other esters disclosed are the monoglyceride of maize oil fatty acids and the ethyl esters of the polyunsaturated fatty acid fraction of cod liver oil.  Emulsifiers specified are sorbitan mono-oleate and polyethylene glycol mono-oleate.  A flavouring agent such as mint, caramel or saccharin may be included in the composition.  Also, the composition may be admixed with milk or fruit juice.
Using CBT-I principles, participants will receive a four-week intervention delivered through a chatbot. The self-administered intervention is comprised of personalized behavioral prescriptions based on stimulus control principles and sleep schedule modification goals using sleep efficiency (SE) criteria. Participants are allowed to self-adjust expectations and make realistic decisions on sleep schedules. Other CBT-I components will be used as on-demand content. The chatbot will facilitate sleep goal setting with the participant, communicate weekly behavioral prescription and CBT-I educational modules, collect sleep diary and provide adaptive feedback and reactive services (e.g. Q\&A conversations) 24/7.
Sepsis poses a significant challenge due its lethality, involving multiple organ dysfunction and impaired immune responses. Among several factors affecting sepsis, monocytes play a crucial role; however, their phenotype, proteomic profile, and function in septic shock remain unclear. Our aim was to fully characterize the subpopulations and proteomic profiles of monocytes seen in septic shock cases and discuss their possible impact on the disease. Peripheral blood monocyte subpopulations were phenotype based on CD14/CD16 expression by flow cytometry, and proteins were extracted from the monocytes of individuals with septic shock and healthy controls to identify changes in the global protein expression in these cells. Analysis using 2D-nanoUPLC-UDMSE identified 67 differentially expressed proteins in shock patients compared to controls, in which 44 were upregulated and 23 downregulated. These proteins are involved in monocyte reprogramming, immune dysfunction, severe hypotension, hypo-responsiveness to vasoconstrictors, vasodilation, endothelial dysfunction, vascular injury, and blood clotting, elucidating the disease severity and therapeutic challenges of septic shock. This study identified critical biological targets in monocytes that could serve as potential biomarkers for the diagnosis, prognosis, and treatment of septic shock, providing new insights into the pathophysiology of the disease.
Cosmetic compositions are widely used to obtain certain benefits like e.g. skin anti-aging, lightening and moisturizing effect. These benefits are delivered by benefit agents (actives) like e.g. anti-oxidants, hyaluronic acid and resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. However, these actives have a certain shelf life beyond which they tend to degrade in terms of chemical activity and/or their color stability. The invention discloses a novel process to prepare cosmetic compositions that improve color stability of resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. The compositions comprise: i) a compound selected from resorcinol, phenylethyl resorcinol, 4-alkyl substituted resorcinol and mixtures thereof; ii) a chelating agent; and iii) a cosmetically acceptable base comprising a water phase and an oil phase. The process for preparing a cosmetic composition comprises the following steps: (a) combining a compound selected from resorcinol, phenylethyl resorcinol, 4-alkyl substituted resorcinol and mixtures thereof with a chelating agent in water; (b) preparing a water phase and an oil phase; (c) combining the water phase and the oil phase to prepare a cosmetically acceptable base; and (d) combining the adduct obtained in step (a) with the cosmetically acceptable base of step (c), wherein the process does not comprise a combination of 4-hexyl resorcinol with ethylenediamine di-succinic acid. A chelating agent can be selected from ethylenediamine tetra-acetic acid, ethylenediamine di-succinic acid and mixtures thereof. Preferably, a combination selected from 4-hexyl resorcinol and ethylenediamine tetra-acetic acid, 4-ethyl resorcinol and ethylenediamine tetra-acetic acid and 4-ethyl resorcinol and ethylenediamine disuccinic acid is used in step (a).
The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
The invention claims a new use of coccidian, especially the application of the coccidian as a vaccine live vector. The invention also claims a live vaccine comprising coccidian vector. The live vaccine comprising coccidian vector is a transgenic coccidian which can express extrinsic protein or a stable transfectant coccidian comprising expressing vector which can express extrinsic protein. The live vaccine comprising coccidian vector can be applied for inducing organism to create humoral immune responses, cellular immune responses (including mucosal immune responses) and memory responses. It is easy to be actualized. And its effect is stable.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to VPRIV in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In clinical studies, 1 of 54 (2%) enzyme treatment-naïve patients treated with VPRIV developed IgG antibodies to VPRIV. One additional patient developed IgG antibodies to VPRIV during an extension study. In both patients, the IgG antibodies to VPRIV were determined to be neutralizing in an in vitro assay. The presence of IgG antibodies to VPRIV was not associated with hypersensitivity reactions. It is unknown if the presence of IgG antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.
Virus infection causes the metabolic disorder of host cells, whereas the metabolic disorder of cells is one of the major causes of tumorigenesis, suggesting that antiviral molecules might possess anti-tumor activities by regulating cell metabolism. As the key regulators of gene expression, long non-coding RNAs (lncRNAs) play vital roles in the regulation of cell metabolism. However, the influence of antiviral lncRNAs on tumorigenesis has not been explored. To address this issue, the antiviral and anti-tumor capacities of shrimp lncRNAs were characterized in this study. The results revealed that shrimp lncRNA06, having antiviral activity in shrimp, could suppress the tumorigenesis of human gastric cancer stem cells (GCSCs) via triggering apoptosis of GCSCs in a cross-species manner. Shrimp lncRNA06 could sponge human miR-17-5p to suppress the stemness of GCSCs via the miR-17-5p-p21 axis. At the same time, shrimp lncRNA06 could bind to ATP synthase subunit beta (ATP5F1B) to enhance the stability of the ATP5F1B protein in GCSCs, thus suppressing the tumorigenesis of GCSCs. The in vivo data demonstrated that shrimp lncRNA06 promoted apoptosis and inhibited the stemness of GCSCs through interactions with ATP5F1B and miR-17-5p, leading to the suppression of the tumorigenesis of GCSCs. Therefore, our findings highlighted that antiviral lncRNAs possessed anti-tumor capacities and that antiviral lncRNAs could be the anti-tumor reservoir for the treatment of human cancers.
In this prospective randomized controlled single-blind study, a total of 25 patients, 16 men, and 9 women were included according to inclusion and exclusion criteria. Patients were randomly assigned to the experimental group (n=12) or the control group (n=13). NMES has applied to the non-affected side ankle dorsiflexors five sessions for a week in both groups. In addition to the experimental group, the cold application was applied on the affected side dorsiflexor muscle skin. The cold application was done on a moist towel for five minutes using a cold pack. A five-minute break was given and a further 5-minute cold application was repeated. The cold application was done simultaneously with NMES. A conventional rehabilitation program was applied to all patients by a physiotherapist. Before and after treatment, both ankle dorsiflexor strength was measured with a force sensor. For force measurements, a force transducer (FC2211-0000-0100-L Compression Load Cell, TE Connectivity company, France) was used. Force transducer signals were received with a data acquisition device (POWERLAB® data acquisition system ADInstruments, Oxford, UK) and evaluated offline on the computer. The measurement values were expressed in kilogram.force (kg.f) and this value was normalized according to body weight.
PURPOSE:To obtain the titled cosmetic having extremely excellent stability, by preparing a W/O-type emulsion by adding water to an oily phase mixed with an oleophilic surfactant, and emulsifying the emulsion with water using a hydrophilic surfactant and an N-(long-chain acyl)amino acid soap. CONSTITUTION:An oleophilic surfactant having an HLB value of <=9 (e.g. sorbitan fatty acid ester, sucrose fatty acid ester, etc.) is mixed in an oily phase such as vegetable oil, wax, etc. and then water is added to the mixture to obtain a W/O-type emulsion. The W/O-type emulsion is emulsified with water using a hydrophilic surfactant having an HLB value of >=10 (e.g. polyglycerol monofatty acid ester, polyoxyethylene alkyl ether, etc.) in combination with an N-(long- chain acyl)amino acid soap to obtain a weakly acidic W/O/W-type emulsion cosmetic. When a water-soluble polymer is added to the outer aqueous phase of said emulsion, it acts as a protective colloid of the emulsion and the stability is further improved.
Nasopalatine duct cysts are difficult to detect on panoramic radiographs due to obstructive shadows and are often overlooked. Therefore, sensitive detection using panoramic radiography is clinically important. This study aimed to create a trained model to detect nasopalatine duct cysts from panoramic radiographs in a graphical user interface-based environment. This study was conducted on panoramic radiographs and CT images of 115 patients with nasopalatine duct cysts. As controls, 230 age- and sex-matched patients without cysts were selected from the same database. The 345 pre-processed panoramic radiographs were divided into 216 training data sets, 54 validation data sets, and 75 test data sets. Deep learning was performed for 400 epochs using pretrained-LeNet and pretrained-VGG16 as the convolutional neural networks to classify the cysts. The deep learning system's accuracy, sensitivity, and specificity using LeNet and VGG16 were calculated. LeNet and VGG16 showed an accuracy rate of 85.3% and 88.0%, respectively. A simple deep learning method using a graphical user interface-based Windows machine was able to create a trained model to detect nasopalatine duct cysts from panoramic radiographs, and may be used to prevent such cysts being overlooked during imaging.
Spirometry and peak cough flow testing (PCF) are commonly used in the respiratory assessment of children with a neuromuscular disorder (NMD). Testing uses two different machines, increases laboratory time, costs and resource utilisation. No studies have assessed the correlation between peak expiratory flow (PEF) obtained from spirometry and PCF in children with NMD using one device. An audit of children with a NMD managed at the Children's Hospital at Westmead in 2022-2024 aged < 20 years who performed spirometry and PCF testing on the same device (Vyaire Body BoxTM, Ultrasonic flow meter-based, or Vyaire PneumotachographTM, Pneumotach flow meter-based; Germany) was conducted to assess the correlation between PCF and PEF. Fifty-one sets of testing were identified, and 40 subjects (9F) had reproducible testing and were included. Median (range) age was 14.95 (7.20-19.00) years. Median PEF (L/min) was 4.05 (1.22-10.26) and median PCF (L/min) was 4.29 (1.69-10.82). PEF and PCF had a strong Pearson's correlation coefficient, (R = 0.97, p = 0.03). The coefficient of determination was 0.93. If laboratory resources permit, spirometry should be the test of choice for children with NMD. On average, spirometry required multiple practices to achieve reproducibility to meet ATS/ERS standards. PCF testing can be utilised for children where performing technically acceptable spirometry is not possible.
Integrating disease screening data and genomic data for host and pathogen populations into prediction models provides breeders and pathologists with a unified framework to develop disease resistance. Developing disease resistance in crops typically consists of exposing breeding populations to a virulent strain of the pathogen that is causing disease. While including a diverse set of pathogens in the experiments would be desirable for developing broad and durable disease resistance, it is logistically complex and uncommon, and limits our capacity to implement dual (host-by-pathogen)-genome prediction models. Data from an alternative disease screening system that challenges a diverse sweet corn population with a diverse set of pathogen isolates are provided to demonstrate the changes in genetic parameter estimates that result from using genomic data to provide connectivity across sparsely tested experimental treatments. An inflation in genetic variance estimates was observed when among isolate relatedness estimates were included in prediction models, which was moderated when host-by-pathogen interaction effects were incorporated into models. The complete model that included genomic similarity matrices for host, pathogen, and interaction effects indicated that the proportion of phenotypic variation in lesion size that is attributable to host, pathogen, and interaction effects was similar. Estimates of the stability of lesion size predictions for host varieties inoculated with different isolates and the stability of isolates used to inoculate different hosts were also similar. In this pathosystem, genetic parameter estimates indicate that host, pathogen, and host-by-pathogen interaction predictions may be used to identify crop varieties that are resistant to specific virulence mechanisms and to guide the deployment of these sources of resistance into pathogen populations where they will be more effective.
The invention discloses a pharmaceutical composition and a preparation method, a preparation and application thereof. The pharmaceutical composition comprises radix angelicae, rhizoma dioscoreae and poria cocos in a weight ratio of 1-3:1-3:1-3. The preparation method includes the steps of pretreatment, coarse pulverization, superfine pulverization and blending. The preparation is prepared into powder, tablets, granules, capsules, dripping pills, honeyed pills or external application by adding pharmaceutically acceptable minor ingredients into the pharmaceutical composition. The pharmaceutical composition is applied to preparation of whitening and beautifying drugs or cosmetics. The pharmaceutical composition is prepared by blending active pharmaceutical ingredients according to a precise composition, achieves whitening and beautifying effects by performing compatibility according to physical and chemical properties and active constituents of the active pharmaceutical ingredients, and has the advantages of high bioavailability, high active constituent dissolution speed, good pharmaceutical absorption effect and little side effect.
Thyroid hormone therapy in patients with concomitant diabetes mellitus (see PRECAUTIONS-Drug Interactions, Insulin or Oral Hypoglycemics regarding interaction and dose adjustment with insulin) or insipidus or adrenal cortical insufficiency may aggravate the intensity of their symptoms. Appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. 

The therapy of myxedema coma requires simultaneous administration of glucocorticoids. (See PRECAUTIONS-Adjunctive Therapy). 

Hypothyroidism decreases and hyperthyroidism increases the sensitivity to anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on anticoagulants and dosage of the latter agents adjusted on the basis of frequent prothrombin time determinations.

Oral therapy should be resumed as soon as the clinical situation has been stabilized and the patient is able to take oral medication. If L-thyroxine rather than liothyronine sodium is used in initiating oral therapy, the physician should bear in mind that there is a delay of several days in the onset of L-thyroxine activity and that intravenous therapy should be discontinued gradually.
The feedback ES will be operationalized as a visual graphic of their personal performance screening and/or delivering SafERteens in relation to the mean of the provider group and/or towards a pre-set standard (i.e., screening 75% of adolescents; delivery rate of 75% of eligible youth). Personalized feedback or none will be randomized on a monthly basis.
A compound capable of inhibiting the physiological activity of lysophosphatidic acid (LPA) and being useful as a preventive or therapeutic agent for diseases whose prevention and treatment can be effectively promoted by inhibition of the physiological activity of LPA, for example, diseases in which LPA receptor is instrumental. In particular, there is provided an azole compound of the formula: (1) (wherein the ring A is isoxazole, etc.; R1 is a substituted or unsubstituted aryl, etc.; R2 is a hydrogen atom, etc.; and R3 is a substituted or unsubstituted alkyl, etc.), or a pharmaceutically acceptable salt.